| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Amy M Pooler, Manuela Polydoro, Susanne Wegmann, Samantha B Nicholls, Tara L Spires-Jones, Bradley T Hyma. Propagation of tau pathology in Alzheimer's disease: identification of novel therapeutic targets. Alzheimer's research & therapy. vol 5. issue 5. 2014-06-12. PMID:24152385. |
accumulation and aggregation of the microtubule-associated protein tau are a pathological hallmark of neurodegenerative disorders such as alzheimer's disease (ad). |
2014-06-12 |
2023-08-12 |
mouse |
| Mingzhang Gao, Min Wang, Qi-Huang Zhen. Concise and high-yield synthesis of T808 and T808P for radiosynthesis of [(18)F]-T808, a PET tau tracer for Alzheimer's disease. Bioorganic & medicinal chemistry letters. vol 24. issue 1. 2014-06-12. PMID:24309505. |
concise and high-yield synthesis of t808 and t808p for radiosynthesis of [(18)f]-t808, a pet tau tracer for alzheimer's disease. |
2014-06-12 |
2023-08-12 |
Not clear |
| Steven E Arnold, Jon B Toledo, Dina H Appleby, Sharon X Xie, Li-San Wang, Young Baek, David A Wolk, Edward B Lee, Bruce L Miller, Virginia M-Y Lee, John Q Trojanowsk. Comparative survey of the topographical distribution of signature molecular lesions in major neurodegenerative diseases. The Journal of comparative neurology. vol 521. issue 18. 2014-06-11. PMID:23881776. |
these include: 1) amyloid-β and tau lesions in alzheimer's disease; 2) tau lesions in three other tauopathies including pick's disease, progressive supranuclear palsy and corticobasal degeneration; 3) α-synuclein inclusion ratings in four synucleinopathies including parkinson's disease, parkinson's disease with dementia, dementia with lewy bodies, and multiple system atrophy; and 4) tdp-43 lesions in two tdp-43 proteinopathies, including frontotemporal lobar degeneration associated with tdp-43 and amyotrophic lateral sclerosis. |
2014-06-11 |
2023-08-12 |
Not clear |
| Scott A Yuzwa, Adrienne H Cheung, Mark Okon, Lawrence P McIntosh, David J Vocadl. O-GlcNAc modification of tau directly inhibits its aggregation without perturbing the conformational properties of tau monomers. Journal of molecular biology. vol 426. issue 8. 2014-06-09. PMID:24444746. |
the aggregation of the microtubule-associated protein tau into paired helical filaments to form neurofibrillary tangles constitutes one of the pathological hallmarks of alzheimer's disease. |
2014-06-09 |
2023-08-12 |
mouse |
| George S Bloo. Amyloid-β and tau: the trigger and bullet in Alzheimer disease pathogenesis. JAMA neurology. vol 71. issue 4. 2014-06-09. PMID:24493463. |
amyloid-β and tau: the trigger and bullet in alzheimer disease pathogenesis. |
2014-06-09 |
2023-08-12 |
Not clear |
| Mitsuru Shinohara, Shinsuke Fujioka, Melissa E Murray, Aleksandra Wojtas, Matthew Baker, Anne Rovelet-Lecrux, Rosa Rademakers, Pritam Das, Joseph E Parisi, Neill R Graff-Radford, Ronald C Petersen, Dennis W Dickson, Guojun B. Regional distribution of synaptic markers and APP correlate with distinct clinicopathological features in sporadic and familial Alzheimer's disease. Brain : a journal of neurology. vol 137. issue Pt 5. 2014-06-09. PMID:24625695. |
familial alzheimer's disease had greater striatal tau pathology than sporadic alzheimer's disease. |
2014-06-09 |
2023-08-12 |
Not clear |
| Mitsuru Shinohara, Shinsuke Fujioka, Melissa E Murray, Aleksandra Wojtas, Matthew Baker, Anne Rovelet-Lecrux, Rosa Rademakers, Pritam Das, Joseph E Parisi, Neill R Graff-Radford, Ronald C Petersen, Dennis W Dickson, Guojun B. Regional distribution of synaptic markers and APP correlate with distinct clinicopathological features in sporadic and familial Alzheimer's disease. Brain : a journal of neurology. vol 137. issue Pt 5. 2014-06-09. PMID:24625695. |
region-specific amyloid-β₄₂ accumulation might account for differences in the relative amounts of tau pathology and clinical symptoms in familial and sporadic alzheimer's disease. |
2014-06-09 |
2023-08-12 |
Not clear |
| Marie Lise Frandemiche, Sandrine De Seranno, Travis Rush, Eve Borel, Auréliane Elie, Isabelle Arnal, Fabien Lanté, Alain Buisso. Activity-dependent tau protein translocation to excitatory synapse is disrupted by exposure to amyloid-beta oligomers. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 34. issue 17. 2014-06-09. PMID:24760868. |
recently, it has emerged that tau participates in synaptic function as part of the molecular pathway leading to amyloid-beta (aβ)-driven synaptotoxicity in the context of alzheimer's disease. |
2014-06-09 |
2023-08-13 |
human |
| Tzu-Chieh Hung, Tung-Ti Chang, Ming-Jen Fan, Cheng-Chun Lee, Calvin Yu-Chian Che. In Silico Insight into Potent of Anthocyanin Regulation of FKBP52 to Prevent Alzheimer's Disease. Evidence-based complementary and alternative medicine : eCAM. vol 2014. 2014-06-06. PMID:24899909. |
alzheimer's disease (ad) is caused by the hyperphosphorylation of tau protein aggregation. |
2014-06-06 |
2023-08-13 |
Not clear |
| Adam Klin. Apolipoprotein E, amyloid-ß clearance and therapeutic opportunities in Alzheimer's disease. Alzheimer's research & therapy. vol 4. issue 4. 2014-06-05. PMID:22929359. |
alzheimer's disease (ad) is a progressive neurodegenerative disease characterised by extracellular amyloid-ß (aß) and intraneuronal tau protein brain pathologies. |
2014-06-05 |
2023-08-12 |
Not clear |
| Amy M Pooler, Wendy Noble, Diane P Hange. A role for tau at the synapse in Alzheimer's disease pathogenesis. Neuropharmacology. vol 76 Pt A. 2014-06-05. PMID:24076336. |
a role for tau at the synapse in alzheimer's disease pathogenesis. |
2014-06-05 |
2023-08-12 |
mouse |
| Amy M Pooler, Wendy Noble, Diane P Hange. A role for tau at the synapse in Alzheimer's disease pathogenesis. Neuropharmacology. vol 76 Pt A. 2014-06-05. PMID:24076336. |
alzheimer's disease (ad) is characterized by brain deposition of amyloid plaques and tau neurofibrillary tangles along with steady cognitive decline. |
2014-06-05 |
2023-08-12 |
mouse |
| b' J Chu, E Lauretti, A Di Meco, D Pratic\\xc3\\xb. FLAP pharmacological blockade modulates metabolism of endogenous tau in vivo\\xc2\\xa0. Translational psychiatry. vol 3. 2014-06-05. PMID:24301651.' |
these data establish a novel functional role for flap in the metabolism of tau, and together with its known aβ modulatory effect they suggest that its pharmacological inhibition could represent a novel therapeutic opportunity for alzheimer's disease. |
2014-06-05 |
2023-08-12 |
mouse |
| Thomas McAvoy, Michael E Lassman, Daniel S Spellman, Zhenlian Ke, Bonnie J Howell, Oitak Wong, Lan Zhu, Michael Tanen, Arie Struyk, Omar F Laterz. Quantification of tau in cerebrospinal fluid by immunoaffinity enrichment and tandem mass spectrometry. Clinical chemistry. vol 60. issue 4. 2014-06-05. PMID:24566260. |
cerebrospinal fluid (csf) tau is a common biomarker for alzheimer disease (ad). |
2014-06-05 |
2023-08-12 |
Not clear |
| Kurt R Brunden, Nicola M Gardner, Michael J James, Yuemang Yao, John Q Trojanowski, Virginia M-Y Lee, Ian Paterson, Carlo Ballatore, Amos B Smit. MT-Stabilizer, Dictyostatin, Exhibits Prolonged Brain Retention and Activity: Potential Therapeutic Implications. ACS medicinal chemistry letters. vol 4. issue 9. 2014-06-05. PMID:24900764. |
inclusions comprising the microtubule (mt)-stabilizing protein, tau, are found within neurons in the brains of patients with alzheimer's disease and related neurodegenerative disorders that are broadly referred to as tauopathies. |
2014-06-05 |
2023-08-13 |
mouse |
| Jing Zhang, Hayley A Mattison, Changqin Liu, Carmen Ginghina, Peggy Auinger, Michael P McDermott, Tessandra Stewart, Un Jung Kang, Kevin C Cain, Min Sh. Longitudinal assessment of tau and amyloid beta in cerebrospinal fluid of Parkinson disease. Acta neuropathologica. vol 126. issue 5. 2014-06-02. PMID:23644819. |
in addition, alterations of the levels of total tau, phosphorylated tau [181p], and amyloid beta 1-42 in cerebrospinal fluid have been reported in patients with sporadic parkinson disease and asymptomatic carriers of leucine-rich repeat kinase 2 mutations, in patterns that clearly differ from those typically described for patients with alzheimer disease. |
2014-06-02 |
2023-08-12 |
Not clear |
| Jing Zhang, Hayley A Mattison, Changqin Liu, Carmen Ginghina, Peggy Auinger, Michael P McDermott, Tessandra Stewart, Un Jung Kang, Kevin C Cain, Min Sh. Longitudinal assessment of tau and amyloid beta in cerebrospinal fluid of Parkinson disease. Acta neuropathologica. vol 126. issue 5. 2014-06-02. PMID:23644819. |
these results are one of the very first pieces of evidence suggesting that tau and amyloid beta are critically involved in early parkinson disease progression, potentially by a different mechanism than that in alzheimer disease, although their applications as parkinson disease progression markers will likely require the addition of other proteins. |
2014-06-02 |
2023-08-12 |
Not clear |
| Heiko Braak, Henrik Zetterberg, Kelly Del Tredici, Kaj Blenno. Intraneuronal tau aggregation precedes diffuse plaque deposition, but amyloid-β changes occur before increases of tau in cerebrospinal fluid. Acta neuropathologica. vol 126. issue 5. 2014-06-02. PMID:23756600. |
in comparison to the levels in age and gender-matched controls, reduced levels of pathological amyloid-β protein in cerebrospinal fluid routinely precede the onset of alzheimer's disease-related symptoms by several years, whereas elevated soluble abnormal tau fractions (phosphorylated tau, total tau protein) in cerebrospinal fluid are detectable only with the onset and progression of clinical symptoms. |
2014-06-02 |
2023-08-12 |
Not clear |
| Jon B Toledo, Ane Korff, Leslie M Shaw, John Q Trojanowski, Jing Zhan. CSF α-synuclein improves diagnostic and prognostic performance of CSF tau and Aβ in Alzheimer's disease. Acta neuropathologica. vol 126. issue 5. 2014-06-02. PMID:23812319. |
csf α-synuclein improves diagnostic and prognostic performance of csf tau and aβ in alzheimer's disease. |
2014-06-02 |
2023-08-12 |
human |
| Jon B Toledo, Ane Korff, Leslie M Shaw, John Q Trojanowski, Jing Zhan. CSF α-synuclein improves diagnostic and prognostic performance of CSF tau and Aβ in Alzheimer's disease. Acta neuropathologica. vol 126. issue 5. 2014-06-02. PMID:23812319. |
in this investigation, we report the assessment of α-synuclein (α-syn) in cerebrospinal fluid (csf) and its association with csf total tau (t-tau), phosphorylated tau181 (p-tau181), and amyloid beta1-42 (aβ1-42) in subjects of the alzheimer's disease neuroimaging initiative (adni; n = 389), with longitudinal clinical assessments. |
2014-06-02 |
2023-08-12 |
human |